Compare Stocks: PBYI, ADMA, CTMX, and TRDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.62 +0.4%	$9.15	$7.21 ▼ $20.46	$2.15B	0.78	1.91 million shs	1.40 million shs
CTMX CytomX Therapeutics	$3.71 +0.8%	$3.49	$1.90 ▼ $8.21	$801.87M	2.14	3.05 million shs	2.30 million shs
PBYI Puma Biotechnology	$9.55 +1.5%	$8.53	$4.30 ▼ $9.73	$485.74M	1.24	323,338 shs	185,909 shs
TRDA Entrada Therapeutics	$7.13 -0.6%	$7.06	$5.02 ▼ $16.45	$279.18M	-0.25	261,480 shs	341,729 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+0.42%	+3.00%	+3.89%	+20.70%	-43.08%
CTMX CytomX Therapeutics	+0.82%	+15.58%	+10.75%	+23.67%	+75.00%
PBYI Puma Biotechnology	+1.49%	+5.41%	+19.52%	+35.85%	+86.16%
TRDA Entrada Therapeutics	-0.56%	+1.86%	+0.99%	+11.93%	+34.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.62 +0.4%	$9.15	$7.21 ▼ $20.46	$2.15B	0.78	1.91 million shs	1.40 million shs
CTMX CytomX Therapeutics	$3.71 +0.8%	$3.49	$1.90 ▼ $8.21	$801.87M	2.14	3.05 million shs	2.30 million shs
PBYI Puma Biotechnology	$9.55 +1.5%	$8.53	$4.30 ▼ $9.73	$485.74M	1.24	323,338 shs	185,909 shs
TRDA Entrada Therapeutics	$7.13 -0.6%	$7.06	$5.02 ▼ $16.45	$279.18M	-0.25	261,480 shs	341,729 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+0.42%	+3.00%	+3.89%	+20.70%	-43.08%
CTMX CytomX Therapeutics	+0.82%	+15.58%	+10.75%	+23.67%	+75.00%
PBYI Puma Biotechnology	+1.49%	+5.41%	+19.52%	+35.85%	+86.16%
TRDA Entrada Therapeutics	-0.56%	+1.86%	+0.99%	+11.93%	+34.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	94.04% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	220.75% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-37.17% Downside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	148.95% Upside

Current Analyst Ratings Breakdown

Latest PBYI, ADMA, CTMX, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/31/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/12/2026	TRDA Entrada Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
8/4/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.22	$0.66 per share	14.65	$1.82 per share	5.29
CTMX CytomX Therapeutics	$18.30M	44.17	N/A	N/A	$1.39 per share	2.67
PBYI Puma Biotechnology	$228.40M	2.16	$0.85 per share	11.28	$2.68 per share	3.56
TRDA Entrada Therapeutics	$25.42M	10.92	N/A	N/A	$5.99 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	13.74	11.32	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	18.37	68.21	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest PBYI, ADMA, CTMX, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
CTMX CytomX Therapeutics	N/A	9.36	9.36
PBYI Puma Biotechnology	N/A	2.91	2.64
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
CTMX CytomX Therapeutics	67.77%
PBYI Puma Biotechnology	61.29%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
CTMX CytomX Therapeutics	3.80%
PBYI Puma Biotechnology	22.20%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	223.99 million	215.25 million	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
PBYI Puma Biotechnology	200	51.62 million	40.16 million	Optionable
TRDA Entrada Therapeutics	110	38.94 million	35.24 million	Optionable

PBYI, ADMA, CTMX, and TRDA Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen

September 5 at 1:31 AM | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Wall Street Zen

September 5 at 1:29 AM | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 4 at 6:52 AM | insidertrades.com

BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA

September 4 at 3:20 AM | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 3 at 9:12 PM | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,361.28 in Stock

September 3 at 9:12 PM | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 32,263 Shares of Stock

September 3 at 9:12 PM | marketbeat.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2 at 4:30 PM | globenewswire.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

September 1, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

August 31, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,922 Shares

August 31, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 44,259 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 31, 2026 | marketbeat.com

300,575 Shares in Entrada Therapeutics, Inc. $TRDA Bought by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock

August 27, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells 14,569 Shares of Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 21,623 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 26,522 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

5AM Venture Management LLC Acquires Shares of 4,056,379 Entrada Therapeutics, Inc. $TRDA

August 26, 2026 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for TRDA

August 12, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of Stock

August 11, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI, ADMA, CTMX, and TRDA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.62 +0.04 (+0.42%)

As of 09/4/2026 04:00 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CytomX Therapeutics NASDAQ:CTMX

$3.71 +0.03 (+0.82%)

As of 09/4/2026 04:00 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Puma Biotechnology NASDAQ:PBYI

$9.55 +0.14 (+1.49%)

As of 09/4/2026 04:00 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Entrada Therapeutics NASDAQ:TRDA

$7.13 -0.04 (-0.56%)

As of 09/4/2026 04:00 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBYI, ADMA, CTMX, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBYI, ADMA, CTMX, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBYI, ADMA, CTMX, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI, ADMA, CTMX, and TRDA Company Descriptions

ADMA Biologics NASDAQ:ADMA

CytomX Therapeutics NASDAQ:CTMX

Puma Biotechnology NASDAQ:PBYI

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBYI, ADMA, CTMX, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBYI, ADMA, CTMX, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBYI, ADMA, CTMX, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI, ADMA, CTMX, and TRDA Company Descriptions

ADMA Biologics NASDAQ:ADMA

CytomX Therapeutics NASDAQ:CTMX

Puma Biotechnology NASDAQ:PBYI

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools